Second Chance for Moms Act
The Second Chance for Moms Act of 2025 would require a new warning on the labeling for the abortion drug mifepristone, stating that its abortifacient effects can be counteracted by natural progesterone and that such progesterone is considered safe in the first trimester by the American Society for Reproductive Medicine. The act also directs the creation of a toll-free, 24/7 hotline under the Public Health Service Act to provide information to women seeking to reverse the effects of mifepristone, with referrals limited to health care providers that offer abortion pill reversal services. The warning label would take effect six months after enactment. The hotline would be funded through grants or contracts and would specifically route referrals to providers offering reversal services. In short, the bill seeks to drive public messaging about reversing mifepristone’s effects and to create a government-backed helpline to connect women with abortion pill reversal providers, aligning labeling requirements with a federally supported information and referral pathway.
Key Points
- 1Adds a conspicuous warning to mifepristone labeling stating that its effects can be counteracted by natural progesterone, and mentions ASRM’s view on safety in the first trimester, with a hotline number to be provided.
- 2Effective date for the warning label is six months after enactment.
- 3Creates a toll-free, 24/7 hotline under Title X to provide information to women seeking to reverse the effects of mifepristone.
- 4Hotline referrals are restricted to health care providers that offer abortion pill reversal services.
- 5Funding for the hotline would be via grants or contracts under the Public Health Service Act (and the hotline is intended to refer only to reversal providers).